Publications by authors named "Kevin R Webster"

Claim this Profile
S
Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation.
Evan J McMahon, Alexander G Cioffi, Patrick R Visperas, Yueqing Lin, Michael Shaghafi, Kevin R Webster

Structure· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.
Adina Gerson-Gurwitz, Nathan P Young, Vikas K Goel, Boreth Eam, Craig R Stumpf, Kevin R Webster

Front Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting mutant KRAS.
Daniel A Erlanson, Kevin R Webster

Curr Opin Chem Biol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation.
Sujata Jana, Rucha Deo, Rowan P Hough, Yuzhen Liu, Jessie L Horn, Kevin R Webster

JCI Insight· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice.
Tarjani Shukla, June Bryan de la Peña, John M Perish, Jonathan E Ploski, Craig R Stumpf, Kevin R Webster

Neurotherapeutics· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Peggy A Thompson, Boreth Eam, Nathan P Young, Sarah Fish, Joan Chen, Kevin R Webster

Mol Cancer Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
Justin T Ernst, Peggy A Thompson, Christian Nilewski, Paul A Sprengeler, Samuel Sperry, Kevin R Webster

J Med Chem· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Yichen Xu, Mauro Poggio, Hyun Yong Jin, Zhen Shi, Craig M Forester, Kevin R Webster

Nat Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nociceptor Translational Profiling Reveals the Ragulator-Rag GTPase Complex as a Critical Generator of Neuropathic Pain.
Salim Megat, Pradipta R Ray, Jamie K Moy, Tzu-Fang Lou, Paulino Barragán-Iglesias, Kevin R Webster

J Neurosci· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Siegfried H Reich, Paul A Sprengeler, Gary G Chiang, James R Appleman, Joan Chen, Kevin R Webster

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent.
Raj N Misra, Hai-yun Xiao, Kyoung S Kim, Songfeng Lu, Wen-Ching Han, Kevin R Webster

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.
Raj N Misra, Hai-yun Xiao, David K Williams, Kyoung S Kim, Songfeng Lu, Kevin R Webster

Bioorg Med Chem Lett· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.
Raj N Misra, Hai-yun Xiao, Kyoung S Kim, Songfeng Lu, Wen-Ching Han, Kevin R Webster

J Med Chem· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues.
Raj N Misra, Hai yun Xiao, David B Rawlins, Weifang Shan, Kristen A Kellar, Kevin R Webster

Bioorg Med Chem Lett· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.
Raj N Misra, David B Rawlins, Hai-yun Xiao, Weifang Shan, Isia Bursuker, Kevin R Webster

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.
Kyoung Soon Kim, S David Kimball, Raj N Misra, David B Rawlins, John T Hunt, Kevin R Webster

J Med Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis